Navigation Links
Triage® C. difficile Panel

ProductsTriage® C. difficile Panel
Company Biosite
Item Triage® C. difficile Panel
Features 
  • The panel with simultaneous, rapid results for C. difficile common antigen (glutamate dehydrogenase) and toxin A.
  • No specialized training or certification needed to perform or interpret
  • Easy To Use
  • Saves time and effort
  • Simple visual interpretation
  • 15-minute turnaround time
  • Rapid information to aid in diagnosis
  • Both positive and negative controls included
  • No need to test separate daily controls
  • Doesnt compromise accuracy for speed
  • Test is fast and definitive
  • Sensitivity for both tests is statistically equivalent to commercially available immunoassays
  • Negative Predictive Value 99.7 percent
Description The Triage® C. difficile Panel is an enzyme immunoassay used for the detection of C. difficile common antigen (glutamate dehydrogenase) and toxin A in human fecal specimens. This test is used as an aid in the diagnosis of C. difficile associated disease and is part of the Triage Microbiology product line, designed to help speed the diagnosis of Clostridium difficile diseases.
Info Biosite
Customer Service:
Web site: http://www.biosite.com

Related medicine products :

1. Triage® Cardiac Panel
2. Triage® TOX Drug Screen
3. Triage® Drugs of Abuse Panels
4. Triage® Profiler Shortness of Breath Panel
5. Triage® Parasite Panel
6. Premier C. difficile Toxin A
7. BD ColorPAC Toxin A C. difficile Rapid Toxin A Test
8. VIDAS Clostridium difficile (Toxin A) assay
9. Xpect Clostridium difficile Toxin A/B Test Kit
10. Clostridium difficile Culture
11. Clostridium difficileCytotoxin Cell Assay
Conventional Digitally-Controlled Water Baths...
... The Dengue virus belongs to the Flavavirus ... commonly throughout the tropics.,Symptoms of Dengue fever ... pain in the back and limbs, lymphadenopathy,maculopapular ... for professional use as an aid in ...
... test is a rapid, qualitative test ... T. cruzi in human serum or ... test is intended primarily as an ... should be confirmed by a supplemental ...
... test is a qualitative one step ... conation of monoclonal,antibody/colloidal gold dye conjugate ... the solid phase. This will selectively ... (typhoid) infection with a high degree ...
Medicine Products:
(Date:3/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... director. Mr. Still was selected through a careful months-long search by the RBMA Board ... to our members, has been a part of building the RBMA since 1992,” said ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of two biometric time and attendance tracking products: the new NCheck Cloud ... NCheck Cloud Bio Attendance uses biometric face recognition to enable users to check ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & Clients ... to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser ... $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a direct ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon ... this procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Silicon Valley Hair ... to announce a new blog post about women’s hair loss. Although hair transplant procedures ... loss as they age. Menopause or genetics can be two reasons a woman may ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
(Date:3/28/2017)... , March 28, 2017 ... to reach USD 8.0 billion by 2025, according to ... increasing incidence of infectious diseases and cancer is expected ... in disease diagnosis over the coming years. In addition, ... of autologous and allogenic stem cell therapy, due to ...
Breaking Medicine Technology: